Crizotinib therapy for congenital embryonal rhabdomyosarcoma associated with an ATIC–ALK gene fusion

Pediatric Blood & CancerEarly View e31148 LETTER TO THE EDITOR Crizotinib therapy for congenital embryonal rhabdomyosarcoma associated with an ATIC–ALK gene fusion Yusuke Akane, Corresponding Author Yusuke Akane [email protected] orcid.org/0000-0001-8090-8235 Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Japan Correspondence Yusuke Akane, Department of Pediatrics, Sapporo Medical University School of Medicine, South-1 West-16, Chuo-ku, Sapporo, Hokkaido, Japan. Email: [email protected]Search for more papers by this authorMasaki Yamamoto, Masaki Yamamoto Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorAkira Takebayashi, Akira Takebayashi orcid.org/0000-0002-9660-1833 Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorRyo Hamada, Ryo Hamada Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorKeita Igarashi, Keita Igarashi Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorMakoto Emori, Makoto Emori Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorShintaro Sugita, Shintaro Sugita Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorKohichi Takada, Kohichi Takada Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorTadashi Hasegawa, Tadashi Hasegawa Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorTakeshi Tsugawa, Takeshi Tsugawa Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this author Yusuke Akane, Corresponding Author Yusuke Akane [email protected] orcid.org/0000-0001-8090-8235 Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Japan Correspondence Yusuke Akane, Department of Pediatrics, Sapporo Medical University School of Medicine, South-1 West-16, Chuo-ku, Sapporo, Hokkaido, Japan. Email: [email protected]Search for more papers by this authorMasaki Yamamoto, Masaki Yamamoto Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorAkira Takebayashi, Akira Takebayashi orcid.org/0000-0002-9660-1833 Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorRyo Hamada, Ryo Hamada Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorKeita Igarashi, Keita Igarashi Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorMakoto Emori, Makoto Emori Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorShintaro Sugita, Shintaro Sugita Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorKohichi Takada, Kohichi Takada Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorTadashi Hasegawa, Tadashi Hasegawa Department of Surgical Pathology, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this authorTakeshi Tsugawa, Takeshi Tsugawa Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, JapanSearch for more papers by this author First published: 17 June 2024 https://doi.org/10.1002/pbc.31148 The abstract of this content was published at SIOP 2021: Successful treatment with crizotinib in refractory congenital embryonal rhabdomyosarcoma with ALK fusion gene. SIOP abstracts. Pediatr Blood Cancer. 2021;68(Suppl 5):e29349. https://doi.org/10.1002/pbc.29349 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Borinstein SC, Steppan D, Hayashi M, et al. Consensus and controversies regarding the treatment of rhabdomyosarcoma. Pediatr Blood Cancer. 2018; 65(2):e26809. doi:10.1002/pbc.26809 10.1002/pbc.26809 Web of Science®Google Scholar 2Sparber-Sauer M, Stegmaier S, Vokuhl C, et al. Rhabdomyosarcoma diagnosed in the first year of life: localized, metastatic, and relapsed disease. Outcome data from five trials and one registry of the Cooperative Weichteilsarkom Studiengruppe (CWS). Pediatr Blood Cancer. 2019; 66(6):e27652. 10.1002/pbc.27652 CASPubMedWeb of Science®Google Scholar 3Ferrari A, Casanova M, Bisogno G, et al. Rhabdomyosarcoma in infants younger than one year old: a report from the Italian Cooperative Group. Cancer. 2003; 97(10): 2597-2604. 10.1002/cncr.11357 CASPubMedWeb of Science®Google Scholar 4Malempati S, Rodeberg DA, Donaldson SS, et al. Rhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group. Cancer. 2011; 117(15): 3493-3501. 10.1002/cncr.25887 PubMedWeb of Science®Google Scholar 5Mossé YP, Voss SD, Lim MS, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children's Oncology Group study. J Clin Oncol. 2017; 35(28): 3215-3221. 10.1200/JCO.2017.73.4830 CASPubMedWeb of Science®Google Scholar 6Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994; 263(5151): 1281-1284. 10.1126/science.8122112 CASPubMedWeb of Science®Google Scholar 7Fischer M, Moreno L, Ziegler DS, et al. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. Lancet Oncol. 2021; 22(12): 1764-1776. 10.1016/S1470-2045(21)00536-2 CASPubMedWeb of Science®Google Scholar 8Foster JH, Voss SD, Hall DC, et al. Activity of crizotinib in patients with ALK-aberrant relapsed/refractory neuroblastoma: a Children's Oncology Group study (ADVL0912). Clin Cancer Res. 2021; 27(13): 3543-3548. 10.1158/1078-0432.CCR-20-4224 CASPubMedWeb of Science®Google Scholar 9Corao DA, Biegel JA, Coffin CM, et al. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status. Pediatr Dev Pathol. 2009; 12(4): 275-283. 10.2350/08-03-0434.1 CASPubMedWeb of Science®Google Scholar 10van Gaal JC, Flucke UE, Roeffen MH, et al. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. J Clin Oncol. 2012; 30(3): 308-315. 10.1200/JCO.2011.37.8588 PubMedWeb of Science®Google Scholar 11Schöffski P, Wozniak A, Leahy MG, et al. The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'. Eur J Cancer. 2018; 94: 156-167. 10.1016/j.ejca.2018.02.011 CASPubMedWeb of Science®Google Scholar 12Gasparini P, Casanova M, Villa R, et al. Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma. Oncotarget. 2016; 7(37): 58903-58914. 10.18632/oncotarget.10368 PubMedGoogle Scholar 13Felkai L, Bánusz R, Kovalszky I, et al. The presence of ALK alterations and clinical relevance of crizotinib treatment in pediatric solid tumors. Pathol Oncol Res. 2019; 25(1): 217-224. 10.1007/s12253-017-0332-1 CASPubMedWeb of Science®Google Scholar 14Parsons DW, Janeway KA, Patton DR, et al. Actionable tumor alterations and treatment protocol enrollment of pediatric and young adult patients with refractory cancers in the National Cancer Institute–Children's Oncology Group Pediatric MATCH trial. J Clin Oncol. 2022; 40(20): 2224-2234. 10.1200/JCO.21.02838 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issuee31148 ReferencesRelatedInformation